Cite

    Isaacs, J. et al. (n.d.). Biosimilars in immune‐mediated inflammatory diseases: initial lessons from the first approved biosimilar anti‐tumour necrosis factor monoclonal antibody. Journal of internal medicine. pp. 41-59. [Online].